<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03362242</url>
  </required_header>
  <id_info>
    <org_study_id>AROAAT1001</org_study_id>
    <nct_id>NCT03362242</nct_id>
  </id_info>
  <brief_title>Study of ARO-AAT in Normal Adult Volunteers</brief_title>
  <official_title>A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effect of ARO-AAT on Serum Alpha-1 Antitrypsin Levels in Normal Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arrowhead Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arrowhead Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and
      pharmacodynamics of single- and multiple-ascending doses of ARO-AAT in healthy adult
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2018</start_date>
  <completion_date type="Anticipated">February 28, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) Possibly or Probably Related to Treatment</measure>
    <time_frame>Part A (single-ascending dose [SAD] phase): up to 29 (+/- 2) days post-dose; Part B (multiple-ascending dose [MAD] phase): up to 113 (+/- 2) days post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of ARO-AAT: Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Part A (single-ascending dose [SAD] phase): up to 48 hours post-dose; Part B (multiple-ascending dose [MAD] phase): up to 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of ARO-AAT: Time to Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>Part A (SAD phase): up to 48 hours post-dose; Part B (MAD phase): up to 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of ARO-AAT: Terminal Elimination Half-Life (tÂ½)</measure>
    <time_frame>Part A (SAD phase): up to 48 hours post-dose; Part B (MAD phase): up to 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of ARO-AAT: Area Under the Plasma Concentration Versus Time Curve From Zero to 24 Hours (AUC0-24)</measure>
    <time_frame>Part A (SAD phase): up to 48 hours post-dose; Part B (MAD phase): up to 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of ARO-AAT: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUCinf)</measure>
    <time_frame>Part A (SAD phase): up to 48 hours post-dose; Part B (MAD phase): up to 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Serum Alpha-1 Antitrypsin (AAT) Levels From Day 1 Pre-Dose Baseline to Nadir</measure>
    <time_frame>Part A (SAD phase): up to 29 (+/- 2) days; Part B (MAD phase): up to 113 (+/- 2) days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response of Serum AAT levels From Nadir Back to Above 20% of Baseline or Above 90 mg/dL</measure>
    <time_frame>Part A (SAD phase): up to 29 (+/- 2) days; Part B (MAD phase): up to 113 (+/- 2) days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Alpha 1-Antitrypsin Deficiency</condition>
  <arm_group>
    <arm_group_label>ARO-AAT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARO-AAT Injection</intervention_name>
    <description>Single or multiple doses of ARO-AAT by subcutaneous (sc) injections</description>
    <arm_group_label>ARO-AAT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sterile Normal Saline (0.9% NaCl)</intervention_name>
    <description>Calculated volume to match active comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women of child bearing potential must have a negative pregnancy test, cannot be
             breastfeeding, and must be willing to use contraception

          -  Willing to provide written informed consent and to comply with study requirements

          -  Non-smoker for at least one year

          -  Normal lung function

          -  No abnormal finding of clinical relevance at Screening

          -  Normal AAT level at Screening visit

        Exclusion Criteria:

          -  Clinically significant health concerns

          -  Regular use of alcohol within one month prior to Screening

          -  Use of an investigational agent or device within 30 days prior to dosing or current
             participation in an investigational study

          -  Recent use of illicit drugs

          -  Use of any drugs or dietary/herbal supplements know to interfere with liver metabolism

        NOTE: additional inclusion/exclusion criteria may apply, per protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>James Hamilton</last_name>
    <phone>626-304-3400</phone>
    <email>jhamilton@arrowheadpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Auckland Clinical Studies Limited</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roselyn Shah</last_name>
      <phone>+64-9-3733474</phone>
      <email>Roselyn.Shah@clinicalstudies.co.nz</email>
    </contact>
    <investigator>
      <last_name>Christian Schwabe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2017</study_first_submitted>
  <study_first_submitted_qc>November 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2017</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

